Pimecrolimus (Elidel (R)) for atopic dermatitis

Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000175
English, French
Authors' objectives:

To summarize the available information on the use of Pimecrolimus 1% cream (trade name Elidel, marketed by Novartis Pharmaceuticals Canada Inc.) in two contexts: 1. short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients two years and older for whom the use of alternative conventional therapies is deemed inadvisable because of potential risks 2. treatment of patients who are inadequately responsive to or intolerant of conventional therapies

Authors' recommendations: Guidance in terms of how this agent can be best used in the treatment of atopic dermatitis is lacking. Neither pimecrolimus nor another new treatment, tacrolimus, has been tested against the optimal use of topical steroids in current practice, and cost-effectiveness data are unavailable. These two factors should be assessed before considering the appropriate place of these agents in the management of atopic dermatitis.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Costs and Cost Analysis
  • Immunosuppressive Agents
  • Tacrolimus
  • Dermatitis, Atopic
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.